References

nogr

Экспериментальная и клиническая гастроэнтерология

Experimental and Clinical Gastroenterology

1682-8658

«Global Media Technologies»

10.31146/1682-8658-ecg-217-9-13-19

nogr-2442

Research Article

ПЕРЕДОВАЯ СТАТЬЯ

LEADING ARTICLE

Новые возможности в диагностике и лечении воспалительных заболеваний кишечника

New opportunities in the diagnosis and treatment of inflammatory bowel diseases

Першко

А. М.

Pershko

A. M.

noemail@neicon.ru

https://orcid.org/0000-0002-1095-8787

Гриневич

В. Б.

Grinevich

V. B.

noemail@neicon.ru

https://orcid.org/0000-0002-2785-6699

Иванюк

Е. С.

Ivanyuk

E. S.

gastroperm@gmail.com

ФГБВОУ ВО «Военно-медицинская академия имени С. М. Кирова», МО РФРоссияS. M. Kirov Military Medical Academy, Ministry of Defense of the Russian FederationRussian Federation

2023

17012024

091319

2024

Першко А.М., Гриневич В.Б., Иванюк Е.С.

Pershko A.M., Grinevich V.B., Ivanyuk E.S.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.nogr.org/jour/article/view/2442

Изучение воспалительных заболеваний кишечника характеризуется динамичностью и новыми открытиями. Расшифрованы тонкие и новые механизмы участия в патогенезе воспалительных заболеваний кишечника генетических и внешнесредовых факторов, а также появились новые классы лекарственных препаратов, позволяющих воздействовать на многие звенья воспалительного процесса. Однако парадоксальность ситуации заключается в том, что чем больше новейших достижений и открытий в области биологии и медицины, тем больше становится «серых пятен» в нашем понимании патогенеза и подходов к терапии этой категории пациентов. При этом фундаментальные проблемы ВЗК, касающиеся снижение риска хирургических вмешательств и восстановления качества жизни пациентов до популяционного уровня, далеки от своего разрешения. В статье обсуждаются новые методические подходы к терапии пациентов с воспалительными заболеваниями кишечника с применением новых классов цитостатиков и гранулоцитарно-макрофагальных колониестимулирующих факторов.

The study of inflammatory bowel disease is characterized by dynamism and new discoveries. Subtle and new mechanisms of participation of genetic and environmental factors in the pathogenesis of inflammatory bowel diseases have been deciphered, as well as new classes of drugs have appeared that allow influencing many parts of the inflammatory process. However, the paradox of the situation lies in the fact that the more recent advances and discoveries in the field of biology and medicine, the more “gray spots” become in our understanding of the pathogenesis and approaches to the treatment of this category of patients. At the same time, the fundamental problems of IBD, related to reducing the risk of surgical interventions and restoring the quality of life of patients to the population level, are far from being resolved. The article discusses new methodological approaches to the treatment of patients with inflammatory bowel diseases using new classes of cytostatics and granulocyte-macrophage colony-stimulating factors.

воспалительные заболевания кишечникаязвенный колитболезнь Кронапрепараты биологической терапиицитостатикигранулоцитарно-макрофагальные колониестимулирующие факторы роста

inflammatory bowel diseaseulcerative colitisCrohn’s diseasebiological therapy drugscytostaticsgranulocyte-macrophage colony stimulating factors

References1

Pershko A.M. [Clinical and morphological variants of nonspecific ulcerative colitis: prognosis of the course and approaches to therapy (clinical and experimental study)]. Diss… med. Science. St. Petersburg, 2000. 38 p. (in Russ.)@@ Першко А. М. Клинико-морфологические варианты неспецифического язвенного колита: прогнозирование течения и подходы к терапии (клинико-экспериментальное исследование). \\Автоферат докт. диссертации. -СПб, 2000. - 38 с.

Pershko A.M., Pronin I. A., Gubonina I. V. [Clinical efficacy of pulse therapy with metipred and cyclophosphamide in patients with acute forms of ulcerative colitis]. [Materials of the scientific-practical conference. Advanced medical technologies for practical healthcare]. St. Petersburg, 2008. 283 P. (in Russ.) @@ Першко А. М., Пронин И. А., Губонина И. В. Клиническая эффективность пульс-терапии метипредом и циклофосфамидом у больных с острыми формами неспецифического язвенного колита. Передовые медицинские технологии практическому здравохранению. Материалы научно-практической конференции. - СПб, 2008. -С.283.

Ashton J.J., Andreoletti G., Coelho T., Haggarty R., Batra A., Afzal N. A., Beattie R. M., Ennis S. Identification of Variants in Genes Associated with Single-gene Inflammatory Bowel Disease by Whole-exome Sequencing. Inflamm Bowel Dis. 2016 Oct;22(10):2317-27. doi: 10.1097/MIB.0000000000000890.

Autschbach F., Braunstein J., Helmke B., Zuna I., Schürmann G., Niemir Z. I., Wallich R., Otto H. F., Meuer S. C. In situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease. Am J Pathol. 1998 Jul;153(1):121-30. doi: 10.1016/S0002-9440(10)65552-6.

Oh S.H., Baek J., Kim K. M., Lee E. J., et al. Is Whole Exome Sequencing Clinically Practical in the Management of Pediatric Crohn’s Disease? Gut Liver. 2015 Nov 23;9(6):767-75. doi: 10.5009/gnl15176.

Bousfiha A., Jeddane L., Picard C., et al. The 2017 IUIS Phenotypic Classification for Primary Immunodeficiencies. J Clin Immunol. 2018 Jan;38(1):129-143. doi: 10.1007/s10875-017-0465-8.

Massey D.C., Bredin F., Parkes M. Use of sirolimus (rapamycin) to treat refractory Crohn’s disease. Gut. 2008 Sep;57(9):1294-6. doi: 10.1136/gut.2008.157297.

Budarf M.L., Labbé C., David G., Rioux J. D. GWA studies: rewriting the story of IBD. Trends Genet. 2009 Mar;25(3):137-46. doi: 10.1016/j.tig.2009.01.001.

Casanova M.J., Chaparro M., Nantes Ó., et al.; EVODIS Study Group*. Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study. Aliment Pharmacol Ther. 2021 Jun;53(12):1277-1288. doi: 10.1111/apt.16361.

Cleynen I., Boucher G., Jostins L., Schumm L. P., et al; International Inflammatory Bowel Disease Genetics Consortium; Parkes M, Vermeire S, Rioux JD, Mansfield J, Silverberg MS, Radford-Smith G, McGovern DP, Barrett JC, Lees CW. Inherited determinants of Crohn’s disease and ulcerative colitis phenotypes: a genetic association study. Lancet. 2016 Jan 9;387(10014):156-67. doi: 10.1016/S0140-6736(15)00465-1.

Cooney R., Baker J., Brain O., Danis B., Pichulik T., Allan P., Ferguson D. J., Campbell B. J., Jewell D., Simmons A. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med. 2010 Jan;16(1):90-7. doi: 10.1038/nm.2069.

de Lange KM, Moutsianas L, Lee JC, Lamb CA, et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet. 2017 Feb;49(2):256-261. doi: 10.1038/ng.3760.

Dieckgraefe B.K., Korzenik J. R. Treatment of active Crohn’s disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet. 2002 Nov 9;360(9344):1478-80. doi: 10.1016/S0140-6736(02)11437-1.

Dohos D., Hanák L., Szakács Z., Kiss S., Párniczky A., Erőss B., Pázmány P., Hegyi P., Sarlós P. Systematic review with meta-analysis: the effects of immunomodulator or biological withdrawal from mono- or combination therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2021 Jan;53(2):220-233. doi: 10.1111/apt.16182.

Gregersen P.K., Olsson L. M. Recent advances in the genetics of autoimmune disease. Annu Rev Immunol. 2009;27:363-91. doi: 10.1146/annurev.immunol. 021908.132653.

Halme L., Paavola-Sakki P., Turunen U., Lappalainen M., Farkkila M., Kontula K. Family and twin studies in inflammatory bowel disease. World J Gastroenterol. 2006 Jun 21;12(23):3668-72. doi: 10.3748/wjg.v12.i23.3668.

Hirschmann S., Atreya R., Englbrecht M., Neurath M. F. Safety and efficacy of intravenous cyclophosphamide pulse therapy in therapy refractory Crohn’s disease patients. J Physiol Pharmacol. 2017 Feb;68(1):57-67. PMID: 28456770.

Jostins L., Ripke S., Weersma R. K., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012 Nov 1;491 (7422):119-24. doi: 10.1038/nature11582.

Kammermeier J., Drury S., James C. T., et al. Targeted gene panel sequencing in children with very early onset inflammatory bowel disease - evaluation and prospective analysis. J Med Genet. 2014 Nov;51(11):748-55. doi: 10.1136/jmedgenet-2014-102624.

Kammermeier J., Dziubak R., Pescarin M., Drury S., et al. Phenotypic and Genotypic Characterisation of Inflammatory Bowel Disease Presenting Before the Age of 2 years. J Crohns Colitis. 2017 Jan;11(1):60-69. doi: 10.1093/ecco-jcc/jjw118.

Kelsen J.R., Dawany N., Moran C. J., et al. Exome sequencing analysis reveals variants in primary immunodeficiency genes in patients with very early onset inflammatory bowel disease. Gastroenterology. 2015 Nov;149(6):1415-24. doi: 10.1053/j.gastro.2015.07.006.

Korzenik J.R., Dieckgraefe B. K., Valentine J. F., Hausman D. F., Gilbert M. J.; Sargramostim in Crohn’s Disease Study Group. Sargramostim for active Crohn’s disease. N Engl J Med. 2005 May 26;352(21):2193-201. doi: 10.1056/NEJMoa041109.

Lala S., Ogura Y., Osborne C., Hor S. Y., Bromfield A., Davies S., Ogunbiyi O., Nuñez G., Keshav S. Crohn’s disease and the NOD2 gene: a role for paneth cells. Gastroenterology. 2003 Jul;125(1):47-57. doi: 10.1016/s0016-5085(03)00661-9.

Lavoie S., Conway K. L., Lassen K. G., et al. The Crohn’s disease polymorphism, ATG16L1 T300A, alters the gut microbiota and enhances the local Th1/Th17 response. Elife. 2019 Jan 22;8: e39982. doi: 10.7554/eLife.39982.

Lees C.W., Satsangi J. Genetics of inflammatory bowel disease: implications for disease pathogenesis and natural history. Expert Rev Gastroenterol Hepatol. 2009 Oct;3(5):513-34. doi: 10.1586/egh.09.45.

Liefferinckx C., Franchimont D. Viewpoint: Toward the Genetic Architecture of Disease Severity in Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2018 Jun 8;24(7):1428-1439. doi: 10.1093/ibd/izy109.

Liu J.Z., van Sommeren S., Huang H., et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015 Sep;47(9):979-986. doi: 10.1038/ng.3359.

Luo Y., de Lange K. M., Jostins L., et al. Exploring the genetic architecture of inflammatory bowel disease by whole-genome sequencing identifies association at ADCY7. Nat Genet. 2017 Feb;49(2):186-192. doi: 10.1038/ng.3761.

Maeda S., Hsu L. C., Liu H., Bankston L. A., Iimura M., Kagnoff M. F., Eckmann L., Karin M. Nod2 mutation in Crohn’s disease potentiates NF-kappaB activity and IL-1beta processing. Science. 2005 Feb 4;307(5710):734-8. doi: 10.1126/science.1103685.

Malchow H., Ewe K., Brandes J. W., Goebell H., Ehms H., Sommer H., Jesdinsky H. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984 Feb;86(2):249-66. PMID: 6140202.

Maynard C.L., Weaver C. T. Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation. Immunol Rev. 2008 Dec;226:219-33. doi: 10.1111/j.1600-065X.2008.00711.x.

McGonagle D., McDermott M.F. A proposed classification of the immunological diseases. PLoS Med. 2006 Aug;3(8): e297. doi: 10.1371/journal.pmed.0030297.

Nguyen H.T., Lapaquette P., Bringer M. A., Darfeuille-Michaud A. Autophagy and Crohn’s disease. J Innate Immun. 2013;5(5):434-43. doi: 10.1159/000345129.

Ogura Y., Bonen D. K., Inohara N., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature. 2001 May 31;411(6837):603-6. doi: 10.1038/35079114.

Ostrowski J., Paziewska A., Lazowska I., Ambrozkiewicz F., et al. Genetic architecture differences between pediatric and adult-onset inflammatory bowel diseases in the Polish population. Sci Rep. 2016 Dec 23;6:39831. doi: 10.1038/srep39831.

Pazmandi J., Kalinichenko A., Ardy R. C., Boztug K. Early-onset inflammatory bowel disease as a model disease to identify key regulators of immune homeostasis mechanisms. Immunol Rev. 2019 Jan;287(1):162-185. doi: 10.1111/imr.12726.

Petermann I., Triggs C. M., Huebner C., Han D. Y., Gearry R. B., Barclay M. L., Demmers P. S., McCulloch A., Ferguson L. R. Mushroom intolerance: a novel diet-gene interaction in Crohn’s disease. Br J Nutr. 2009 Aug;102(4):506-8. doi: 10.1017/S0007114509276446.

Russell R.K., Satsangi J. IBD: a family affair. Best Pract Res Clin Gastroenterol. 2004 Jun;18(3):525-39. doi: 10.1016/j.bpg.2003.12.006.

Schmidt C., Wittig B. M., Moser C., Zeitz M., Stallmach A. Cyclophosphamide pulse therapy followed by azathioprine or methotrexate induces long-term remission in patients with steroid-refractory Crohn’s disease. Aliment Pharmacol Ther. 2006 Jul 15;24(2):343-50. doi: 10.1111/j.1365-2036.2006.02988.x.

Singh S., Fumery M., Sandborn W. J., Murad M. H. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018 Jan;47(2):162-175. doi: 10.1111/apt.14422.

Thein W., Po W. W., Choi W. S., Sohn U. D. Autophagy and Digestive Disorders: Advances in Understanding and Therapeutic Approaches. Biomol Ther (Seoul). 2021 Jul 1;29(4):353-364. doi: 10.4062/biomolther.2021.086.

Yang E., Panaccione N., Whitmire N., et al. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn’s disease. Aliment Pharmacol Ther. 2020 Jun;51(11):1031-1038. doi: 10.1111/apt.15719.

Zhernakova A., van Diemen C. C., Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet. 2009 Jan;10(1):43-55. doi: 10.1038/nrg2489.

The authors declare that there are no conflicts of interest present.